Skip to main content
Clinical Trials/NCT02426645
NCT02426645
Unknown
Not Applicable

Microcirculatory Alteration and Biomarkers: New Approach for Early Assessment of Septic Multi-organ Dysfunction

Prof. Dr. Marc-H. Dahlke, Ph. D.1 site in 1 country25 target enrollmentApril 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
Prof. Dr. Marc-H. Dahlke, Ph. D.
Enrollment
25
Locations
1
Primary Endpoint
Assessment of early post-operative course of novel cellular injury biomarkers as well as microvascular perfusion in critically ill patients with severe sepsis and to collection any first evidence of the association of these markers with the SOFA-Score
Last Updated
7 years ago

Overview

Brief Summary

The aim of this study is to investigate associations between early structural cellular injury and microvascular alteration with progression of septic organ dysfunction according to total SOFA-Score (an ICU-scoring system - the Sequential Organ Failure Assessment Score). Patients will be monitored for renal (TIMP-2, IGFBP7), and intestinal biomarkers (plasma i-FABP) in conjunction with kidney and muscle vascular bed microvascular perfusion analysis assessed by contrast-enhanced ultrasonography (CEUS). In parallel, a comprehensive analysis of patients' immunological status will be conducted using an established, on-site immune monitoring panel.

The ultimate goal of this study is an early identification of septic patients developing multiorgan dysfunction which may facilitate a timely novel intervention in the future to improve outcome.

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
April 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Prof. Dr. Marc-H. Dahlke, Ph. D.
Responsible Party
Sponsor Investigator
Principal Investigator

Prof. Dr. Marc-H. Dahlke, Ph. D.

Professor

University Hospital Regensburg

Eligibility Criteria

Inclusion Criteria

  • Patients ≥18 years of age with severe sepsis and fulfill the following criteria at the admission to ICU:
  • Peritonitis (abdominal infection) and performed source control (either surgically or interventionally)
  • 2 or more criteria for systemic inflammatory response syndrome (temperature \>38° or\<36°; heart rate \>90 beats per minute; respiratory rate \>20 breaths per minute or paCO2 \<32 mmHg; white blood cell count \>12,000/mm3, \<4000mm3 or \>10% immature forms) and serum lactate level of 4mmol/l and more or refractory hypotension - mean arterial pressure \<65mmHg or systolic blood pressure \<90mmHg after fluid challenge of 1000ml or more /30min
  • Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Written informed consent prior to any study procedures

Exclusion Criteria

  • Pre-existing renal-replacement therapy in the pre-operative course
  • Pre-existing shock
  • Acute coronary syndrome
  • Active hemorrhage
  • Known allergy to ultrasound contrast media
  • Anemia with hemoglobin concentration \< 7g/dl
  • Patients not able to give written informed consent

Outcomes

Primary Outcomes

Assessment of early post-operative course of novel cellular injury biomarkers as well as microvascular perfusion in critically ill patients with severe sepsis and to collection any first evidence of the association of these markers with the SOFA-Score

Time Frame: 60 weeks

Secondary Outcomes

  • 28 day mortality(60 weeks)
  • 90 day mortality(60 weeks)
  • Length of ICU stay(60 weeks)
  • Length of hospital stay(60 weeks)
  • Early post-operative course of microvascular perfusion of the kidney and muscle vasculature bed using CEUS(60 weeks)
  • Incidence of acute kidney injury (AKI) within the first 48 hours as based on current Kidney Disease: Improving Global Outcomes (KDIGO) recommendation(60 weeks)
  • Incidence of acute kidney injury (AKI) within the first 7 days as based on current Kidney Disease: Improving Global Outcomes (KDIGO) recommendation(60 weeks)
  • Need for renal replacement therapy (RRT) after admission to ICU(60 weeks)
  • Identification of an "immunological fingerprint" indicating multi-organ dysfunction(60 weeks)

Study Sites (1)

Loading locations...

Similar Trials